Symposium | Understanding the differences between FLT3-ITD and -TKD mutations in AML: Q&A
The AML Hub held a virtual symposium on November 19, 2025, titled Understanding the differences between FLT3-ITD and -TKD mutations in AML: Implications for clinical practice. The symposium ended with...
12 Helmi 7min
Symposium | Implications for clinical practice: Managing AML with FLT3-ITD and -TKD mutations
The AML Hub held a virtual symposium on November 19, 2025, titled Understanding the differences between FLT3-ITD and -TKD mutations in AML: Implications for clinical practice. Here, we share a present...
11 Helmi 14min
Symposium | Comparing treatment options for patients with FLT3-ITD and -TKD mutations
The AML Hub held a webinar on November 19, 2025, titled, Understanding the differences between FLT3-ITD and -TKD mutations in AML: Implications for clinical practice. Here, we share a presentation fro...
19 Tammi 20min
Symposium | FLT3 mutations in AML: Types, prevalence, and clinical significance
The AML Hub held a webinar on November 19, 2025, titled, “Understanding the differences between FLT3-ITD and -TKD mutations in AML: Implications for clinical practice.” Here, we share one of the prese...
14 Tammi 16min
ASH 2025 | Pivekimab sunirine + Ven + Aza in unfit patients with ND CD123+ AML: Phase Ib/II efficacy and safety
Following the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US, the AML Hub was pleased to speak with Gail Roboz, Weill Cornell Medicine, New Yo...
13 Tammi 8min
ASH 2025 | PARADIGM: Azacitidine + venetoclax vs conventional induction in fit adults with ND AML
Following the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US, the AML Hub was pleased to speak with Amir Fathi, Massachusetts General Hospital...
18 Joulu 20257min
Clinical research round-up: Current and emerging treatments for IDH1-mutated AML
The AML Hub was pleased to speak with Eytan Stein, Memorial Sloan Kettering Cancer Center, New York, US. We asked, What are the latest data presented on current and emerging treatments for acute myelo...
6 Marras 20254min
Menin inhibitors in AML: Bridging the gap between trial data and clinical practice
The AML Hub was pleased to speak with Emma Searle, The Christie NHS Foundation Trust, Manchester, UK. We asked for her thoughts on the topic “Menin inhibitors in AML: Bridging the gap between trial da...
24 Loka 20257min
